KYMERA THERAPEUTICS INC (KYMR)
US5015751044 - Common Stock
KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024
KYMR stock results show that Kymera Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase...
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
Commit To Buy Kymera Therapeutics At $17.50, Earn 9% Annualized Using Options
Kymera Therapeutics Enters Oversold Territory (KYMR)
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster...
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start...
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in...
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...
First Week of KYMR March 15th Options Trading
INVO, NAYA announce new board members ahead of merger (NASDAQ:INVO)
INVO Bioscience (INVO) and NAYA Biosciences said they expect their planned merger to close in Q1 and announced several additions to their future combined board. Read more here.
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data...
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
Shares soared and then tumbled Friday after the company offered $275 million in public shares.
Kymera Therapeutics prices $275 million securities offering
Kymera Therapeutics (KYMR) announced on Friday the pricing of an underwritten public offering of ~2.25M common shares and pre-funded warrants to purchase ~8.64M common shares.
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...
Kymera commences $250M public offering (NASDAQ:KYMR)
Kymera Therapeutics (KYMR) said it has commenced an underwritten public offering of $250M of its common stock and pre-funded warrants to buy common stock. Read more here.
Kymera Therapeutics announces public offering of $250M shares of its stock (NASDAQ:KYMR)
Kymera Therapeutics announces a proposed underwritten public offering of $250M shares of its common stock, with an option for additional shares.
Kymera Therapeutics Announces Proposed Public Offering
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
Company’s focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential ...
Kymera stock dips 5% following BofA downgrade (NASDAQ:KYMR)
Shares of Kymera Therapeutics (KYMR) dropped 5% after BofA downgraded the stock to neutral, citing a lack of near-term catalysts. Read more here.